Oxford Biomedica PLC 2021 AR2

The report highlights Oxford Biomedica's strong operational and financial performance in 2021, driven by the large-scale commercial manufacture of over 100 million doses of the Oxford AstraZeneca COVID-19 vaccine. The company expanded its global footprint by establishing Oxford Biomedica Solutions in the US to broaden its viral vector capabilities into the adeno-associated virus (AAV) segment. Additionally, the company secured a £50 million equity investment from Serum Life Sciences to fund the expansion of its Oxbox manufacturing facility. On the ESG front, the company reduced its average environmental impact per FTE by 14% and increased its active apprenticeships to 33.

Company: Oxford Biomedica PLC

Sector: Health Care

Country: United Kingdom

Year: 2021

Type: AR2

Pages: 194

Back to company

Oxford Biomedica PLC

Oxford Biomedica PLC 2021 Annual Report and Accounts

Annual Report And Accounts

The report highlights Oxford Biomedica's strong operational and financial performance in 2021, driven by the large-scale commercial manufacture of over 100 million doses of the Oxford AstraZeneca COVID-19 vaccine. The company expanded its global footprint by establishing Oxford Biomedica Solutions in the US to broaden its viral vector capabilities into the adeno-associated virus (AAV) segment. Additionally, the company secured a £50 million equity investment from Serum Life Sciences to fund the expansion of its Oxbox manufacturing facility. On the ESG front, the company reduced its average environmental impact per FTE by 14% and increased its active apprenticeships to 33.

Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.

Document Details

Report Year

2021

Reporting Period

Jan 1, 2021 - Dec 31, 2021

Fiscal Year

2021

Type

Annual Report with Sustainability Disclosures

Language

English

Pages

 

File Size

 

Standards & Assurance

Reporting Standards

Materiality Assessment

ESG Data?Experimental — AI-extracted data, may contain inaccuracies

Emissions

Scope 1:

Scope 2:

Energy Consumption

Women on Board

Women in Management

Net Zero Target

Employees